Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Edwards Lifesciences (EW) and Royalty Pharma (RPRX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Edwards Lifesciences (EW – Research Report) and Royalty Pharma (RPRX – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Incyte (INCY)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Incyte, with a price target of $92.00. The company’s shares closed last Tuesday at $100.05.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $106.07, a 3.0% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.
See the top stocks recommended by analysts >>
Edwards Lifesciences (EW)
In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Edwards Lifesciences, with a price target of $100.00. The company’s shares closed last Tuesday at $77.05.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $97.44 average price target, representing a 26.7% upside. In a report issued on January 26, William Blair also maintained a Buy rating on the stock.
Royalty Pharma (RPRX)
In a report released today, Chris Schott from J.P. Morgan maintained a Buy rating on Royalty Pharma, with a price target of $50.00. The company’s shares closed last Tuesday at $44.21.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $48.50, which is a 10.0% upside from current levels. In a report issued on January 30, UBS also upgraded the stock to Buy with a $49.00 price target.
